Researchers are preparing to launch a pivotal test of an important malaria vaccine this month — one that global health leaders believe could eventually lead to big reductions in the number of cases and deaths worldwide.
Despite those high hopes, there are also concerns that the theoretical benefits of the vaccine, made by GSK, might not translate into the real world.
To see whether the vaccine lives up to its promise, the World Health Organization and partners have designed a sort of beta rollout of the vaccine, called RTS,S. Beginning April 23, Malawi is expected to start using the vaccine in its routine immunization programs for children. Ghana and Kenya will later do the same.
Read more at STAT…